Virpax Pharmaceuticals, Inc. VRPX

Virpax Pharmaceuticals, Inc. announced a reverse stock split at a ratio of 1-for-15, effective on October 30, 2023. This decision aims to increase the per-share trading price of its common stock to meet the minimum bid price requirement for continued listing on the Nasdaq. The reverse split will reduce the number of outstanding shares, but the overall value of shareholders' investments will remain unchanged. The company believes this move is necessary to enhance its market position and attract potential investors. The reverse stock split is a strategic move to maintain Nasdaq listing, which may influence investor sentiment and market perception.

Virpax Pharmaceuticals, Inc. announced positive results from a dose range finding study of Probudur, a long-acting liposomal bupivacaine formulation, in beagle dogs. The study showed that doses up to 90 mg/kg were well tolerated with no adverse effects. Probudur aims to provide effective pain control post-surgery and reduce opioid reliance. The company is progressing towards its Investigational New Drug application. Positive study results for Probudur could significantly impact future product development and market positioning.

Virpax Pharmaceuticals, Inc. is exploring the use of Molecular Envelope Technology (MET) to develop an intranasal mRNA COVID vaccine, aiming to provide a safer alternative to current lipid-based delivery methods. The company currently utilizes MET for its products Envelta and NobrXiol, which target pain management and epilepsy treatment, respectively. Virpax is also seeking FDA approval for its drug candidates and has cooperative agreements with the NIH and DOD. Additionally, the company is developing nonprescription products to inhibit viral replication and manage pain associated with osteoarthritis. The potential development of an intranasal COVID vaccine using MET could significantly alter Virpax's market position and investor sentiment.

Virpax Pharmaceuticals, Inc. announced that its NES100 dose range finding toxicity study will be presented at The Society of Toxicology's 64th annual meeting in Orlando, FL, from March 16-20, 2025. NES100 is an intranasal peptide designed for managing acute and chronic non-cancer pain, utilizing nanotechnology to enhance delivery to the brain. The company has extended its research agreement with the National Center for Advancing Translational Sciences (NCATS) for NES100's development. Virpax is also developing other non-addictive pain management products and seeking FDA approval for multiple candidates. The presentation of NES100 at a major toxicology meeting and the ongoing collaboration with NCATS indicate significant progress in product development that could enhance market positioning.

Virpax Pharmaceuticals, Inc. announced positive results from a human study utilizing its Molecular Envelope Technology, which aims to enhance drug delivery and efficacy. The study demonstrated promising outcomes, indicating the potential for this technology to improve treatment options in various therapeutic areas. The company is optimistic about the implications of these results for future product development and market opportunities. Positive study results could significantly enhance product development and market positioning for Virpax Pharmaceuticals.

Virpax Pharmaceuticals announces 1-for-10 reverse stock split to comply with Nasdaq's minimum bid price requirement. The reverse stock split is expected to have a moderately noticeable influence on Virpax Pharmaceuticals' future market performance by regaining compliance with Nasdaq's requirements and attracting a broader investor base.

Virpax Pharmaceuticals settles litigation with Sorrento Therapeutics and Scilex Pharmaceuticals, agreeing to pay $6 million and royalties. Settlement may impact financial performance and competitive positioning.

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) announced the completion of a preclinical study for its pain candidate, Probudur, conducted by the U.S. Army Institute of Surgical Research. The study aimed to evaluate Probudur's effectiveness in reducing pain behaviors in a rat model of incisional pain, comparing it to free bupivacaine and Pacira Pharmaceuticals' Exparel. Results indicated that Probudur significantly reduced incision-induced pain behaviors. Probudur is designed for safe pain control during the perioperative period, potentially reducing opioid reliance. Following the news, VRPX stock surged 31.5% to $0.38. The successful preclinical study for Probudur could significantly enhance Virpax's market position and investor sentiment regarding its pain management solutions.

Virpax Pharmaceuticals, Inc. announced positive results from a study of Probudur™, a product designed for combat care, in collaboration with the US Army. The study demonstrated Probudur™'s effectiveness in managing pain, which could enhance treatment options for military personnel. This development aligns with the company's focus on innovative pain management solutions. Positive results from the US Army study could significantly enhance Probudur™'s market potential and investor interest.

Virpax Pharmaceuticals, Inc. announced that Matthew Barnes, the senior director of portfolio management, will present at the Outsourcing in Clinical Trials Conference. This conference gathers over 1,000 industry leaders to discuss clinical trial solutions. Additionally, the company congratulated Dr. Sheila Mathias and Barnes for publishing articles in the DIA Global Forum and the Outsourcing In Clinical Trials Handbook 2025. Virpax is focused on developing non-addictive pain management products and is seeking FDA approval for two drug candidates, Probudur™ and Envelta™, while also pursuing partnerships for nonprescription products. The presentation at a significant industry conference and recent publications may enhance Virpax's visibility and credibility, potentially influencing its market position.

Virpax Pharmaceuticals, Inc. has successfully completed a $6 million follow-on offering, with Spartan Capital Securities acting as the sole placement agent. The funds raised are expected to support the company's ongoing development initiatives and operational needs. The follow-on offering provides additional capital that may enhance financial performance and support product development.

Virpax Pharmaceuticals, Inc. has closed a public offering of $6.0 million in common stock and pre-funded warrants at a price of $0.20 per share. The proceeds will be used for ongoing development activities, including clinical trials for its product candidate Probudur, marketing efforts, and general corporate purposes. Spartan Capital Securities, LLC is the exclusive placement agent for the offering, which was conducted under a registration statement filed with the SEC. The final prospectus is available on the SEC's website. The funding from the public offering is expected to support key development activities, potentially influencing the company's financial performance and product innovation.

Virpax Pharmaceuticals, Inc. has announced the pricing of a public offering of common stock and pre-funded warrants, aiming to raise $6 million. The offering is expected to enhance the company's financial position and support its ongoing development initiatives. The public offering is likely to provide necessary funding for development, impacting financial performance moderately.

Virpax Pharmaceuticals announced positive results from a minipig Dose Range Finding study for Probudur, a long-acting liposomal bupivacaine formulation for pain management. Positive study results for Probudur could lead to significant impact on Virpax Pharmaceuticals' future product development and market performance.

Virpax Pharmaceuticals, Inc. extends agreement with the U.S. Department of Health and Human Services for the development of NES100 for non-cancer pain management. The extension of the agreement with the U.S. Department of Health and Human Services for the development of NES100 has the potential to significantly impact Virpax Pharmaceuticals, Inc.'s future product innovation and competitive positioning.

Spartan Capital Securities, LLC served as the sole placement agent in Virpax Pharmaceuticals, Inc.'s $5.0 million public offering. The public offering could moderately influence Virpax Pharmaceuticals, Inc.'s financial performance and competitive positioning.

Virpax Pharmaceuticals, Inc. closed a $5.0 million public offering of common stock and pre-funded warrants. The public offering is expected to have a moderately noticeable influence on Virpax Pharmaceuticals, Inc.'s financial performance and competitive positioning.

Virpax Pharmaceuticals, Inc. priced a $5.0 million public offering of common stock and pre-funded warrants to fund ongoing activities, including an investigational new drug filing for post operative pain management. The public offering and planned investigational new drug filing are significant strategic moves that could alter the company's trajectory.

Adial Pharmaceuticals appoints Vinay Shah as Chief Financial Officer, effective November 16, 2024. Vinay Shah's appointment as CFO at Adial Pharmaceuticals after serving as CFO at Virpax Pharmaceuticals could have a significant impact on the company's future financial strategy and operational efficiency.

Virpax Pharmaceuticals reported financial results for the second quarter of 2024, including progress on product candidates and recent developments such as securing financing and regaining compliance with Nasdaq listing requirements. The article describes significant developments such as positive study results, financing, and compliance with Nasdaq listing requirements that could have a major impact on Virpax Pharmaceuticals' future performance.

Virpax Pharmaceuticals, Inc. will present at Sidoti Virtual Investor Conference on August 14-15, 2024. The presentation at the investor conference could have a significant impact on Virpax's future performance and market sentiment.

Virpax Pharmaceuticals, Inc. regains compliance with Nasdaq minimum bid price requirement after maintaining a minimum closing bid price of $1.00 for 10 consecutive business days. Regaining compliance with Nasdaq minimum bid price rule is expected to moderately influence the company's financial performance and market sentiment.

Virpax Pharmaceuticals surged over 100% after releasing positive results for a Swine Model pilot study on Probudur, a long-acting pain relief formulation. Positive study results for Probudur and potential to reduce opioid use after surgery could significantly impact Virpax's future and market performance.

Virpax Pharmaceuticals announced positive results of a Swine Model pilot study for Probudur, showing well-tolerated long-term pain relief. Positive study results for Probudur could significantly impact Virpax's future drug development and market performance.

Virpax Pharmaceuticals secured $2.5 million loan financing and reorganized its Board of Directors with four new members appointed. The significant funding and board reorganization are expected to have a major impact on the company's future trajectory and operations.

Virpax Pharmaceuticals to present at 2024 BIO International Convention. Virpax presenting at BIO International Convention may moderately influence its competitive positioning and product innovation.

Virpax Pharmaceuticals, Inc. announced pricing of $2.25 million public offering. The public offering and pricing details are significant for the company's financial performance and future trajectory.

Virpax Pharmaceuticals reported 2024 first quarter results and recent developments, including positive study results for Probudur and recognition for Nanomerics' innovation. Positive study results for Probudur and recognition for Nanomerics' innovation are expected to significantly impact Virpax Pharmaceuticals' future product development and competitive positioning.

Virpax Pharmaceuticals announced results of Maximum Tolerated Dose study for Probudur, a liposomal bupivacaine formulation for pain relief. The study results have the potential to significantly impact Virpax's future product development and market positioning.

Virpax Pharmaceuticals reported 2023 year-end financial results, regained Nasdaq compliance, settled litigation, and made progress on product development. The article highlights significant developments such as regained compliance, settlement agreement, progress on product development, and potential game-changing product candidates.